Examples of using Dose modification in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
No dose modification.
Recommended measures and dose modification.
MCL dose modification after recovery.
Table 1 Adverse reactions requiring dose modification of lenvatinib.
Dose modification based on height is not necessary.
Table 4 provides guidelines for dose modification for patients with renal dysfunction.
Dose modification at day 1 of cycle subsequent to AE.
For clinical management of skin reactions, including dose modification recommendations, see section 4.4.
Dose modification advice for left ventricular dysfunction.
After initiation of lenalidomide therapy, subsequent lenalidomide dose modification in renally impaired patients should be based on individual patient treatment tolerance, as described above.
Dose modification based on elevated hepatic aminotransferases.
In some cases, dose modification may be necessary see section 4.2.
Dose modification of calcium channel blockers should be considered when co.
Table 6: Pegasys dose modification recommendations in paediatric patients.
Dose modification of ribavirin in patients taking 1,000-1,200 mg daily.
Cisplatin dose modification at the start of the cycle of treatment.
Dose modification of Daklinza to manage adverse reactions is not recommended.
FOLFIRI Dose modification when used in combination with ZALTRAP.
Dose modification or interruption guidelines should be followed see section 4.2.
Elderly: No dose modification is required for this age group.
See dose modification for provisions for the modification to dose and dosage schedule.
Table 7: Pegasys dose modification recommendations for toxicities in paediatric patients.
Dose modification of gemcitabine within a cycle for breast cancer, given in combination with paclitaxel.
Table 5: Dose modification of FOLFIRI components due to specific AEs.
Dose modification of Cotellic is independent of vemurafenib dose modification. .
Therefore dose modification is not required for patients with renal function impairment.
Dose modification of INCIVO is not required when administered to hepatitis C patients with mild hepatic impairment Child-Pugh A, score 5-6.
No dose modification of trametinib is required for RAS mutation positive malignancies when taken in combination with dabrafenib.
Dose modification of calcium channel blockers should be considered when co- administered with indinavir/ritonavir as it may result in an increased response.